[Management View]
Merck reported Q2 2025 revenue of $15.8 billion, reflecting a 2% decline due to reduced Gardasil sales in China. Excluding China, global revenue grew 7%, driven by oncology, animal health, and new product launches like WinRevair and Cavaxib. Management emphasized confidence in long-term growth, supported by robust demand for KEYTRUDA and a diversified pipeline. A $3 billion cost optimization initiative was announced to reinvest savings into high-growth areas, including R&D and commercial launches.

[Outlook]
Merck provided full-year 2025 revenue guidance of $64.3-$65.3 billion, representing 1%-2% growth excluding FX impacts. EPS guidance was set at $8.87-$8.97. The company expects FDA decisions for subcutaneous pembrolizumab and WinRevair’s PAH label update in September and October 2025, respectively. The Verona Pharma acquisition is expected to close in Q4 2025, adding Ohtober, a novel COPD therapy, to Merck's portfolio.

[Financial Performance]
- Total revenue: $15.8 billion (-2% YoY)
- KEYTRUDA sales: $8 billion (+9% YoY)
- Gardasil sales: $1.1 billion (-55% YoY, primarily due to China)
- Animal health sales: +11% YoY
- Gross margin: 82.2% (non-GAAP)
- EPS: $2.13 (non-GAAP)

[Q&A Highlights]
Question 1: Can you elaborate on the cadence trial outcomes and their implications for registration in HFTEP?
Answer: The primary focus is on pulmonary vascular resistance (PVR) as the most critical signal. While six-minute walk distance is important, PVR is the key metric for success. FDA may require a Phase III trial for registration depending on the data.

Question 2: How do you view the ex-US opportunity for WinRevair given pricing pressures?
Answer: The ex-US launch is early, with broader reimbursement expected in H2 2025. Markets like Germany are showing good uptake. Japan approval was recently secured, and pricing adjustments were made in Q2. The global market size is approximately 90,000 patients, split evenly between the US and ex-US.

Question 3: How will the $3 billion cost optimization impact operating margins and OpEx growth?
Answer: The savings will be reinvested into R&D and SG&A to support pipeline advancement and new product launches. Operating expenses will grow, but at a more productive level, ensuring long-term growth.

Question 4: What is the outlook for Gardasil sales in the US and China?
Answer: US growth is driven by price and demand, offset by CDC purchasing patterns. No shipments to China are planned for 2025 due to elevated inventory and soft demand. The company will reassess the situation for 2026.

Question 5: How does Merck approach diligence in assets from Chinese versus Western companies?
Answer: Merck prioritizes first-mover advantage and transformative science. The Verona Pharma acquisition aligns with this strategy, offering a novel COPD therapy approved in the US. Chinese assets lacked similar positioning.

Question 6: Can you confirm the progress of the Lenovo PD-1 VEGF bispecific program?
Answer: The program is proceeding as planned, with no changes to Merck's commitment. External factors do not impact the development timeline.

Question 7: What is the expected trajectory for WinRevair patient adds and earlier-line adoption?
Answer: Patient adds have been steady at 400-500 per month. Adoption in less severe patients is increasing, supported by positive Hyperion and Zenith trial results.

Question 8: How does the IRA orphan drug exclusion impact KEYTRUDA’s pricing timeline?
Answer: The exclusion shifts KEYTRUDA’s IRA selection from 2028 to 2029. Biosimilar presence by then may further impact its inclusion.

Question 9: What offsets does Merck see for KEYTRUDA’s loss of exclusivity?
Answer: Merck anticipates over $50 billion in new product opportunities across oncology, cardiometabolic, HIV, immunology, and animal health. Subcutaneous KEYTRUDA and pipeline launches will mitigate revenue impact.

Question 10: What combinations and indications are planned for enlicitide?
Answer: Enlicitide will serve as a platform for combinations targeting LDL, Lp(a), and inflammatory axes. It aims to drive cardiovascular outcomes with incremental improvements.

[Sentiment Analysis]
Management displayed confidence in pipeline strength and long-term growth, emphasizing strategic reinvestment and diversification. Analysts were focused on pipeline execution, pricing dynamics, and the impact of regulatory changes. The tone was constructive, with detailed responses to key concerns.

[Quarterly Comparison]
| Metric | Q2 2025 | Q2 2024 | YoY Change |
|-----------------------|---------------|---------------|------------|
| Total Revenue | $15.8 billion | $16.1 billion | -2% |
| KEYTRUDA Sales | $8 billion | $7.3 billion | +9% |
| Gardasil Sales | $1.1 billion | $2.4 billion | -55% |
| Animal Health Sales | +11% | +8% | +3pp |
| Gross Margin (non-GAAP)| 82.2% | 80.9% | +1.3pp |
| EPS (non-GAAP) | $2.13 | $2.06 | +3.4% |

[Risks and Concerns]
- Gardasil sales in China remain a significant headwind due to elevated inventory and soft demand.
- Biosimilar competition for pembrolizumab in Argentina impacted revenues.
- Tariff risks for 2026 remain uncertain, with potential implications for cost structure.
- Regulatory changes under the IRA could affect KEYTRUDA’s pricing timeline.

[Final Takeaway]
Merck’s Q2 2025 results reflect resilience amid challenges, with strong growth in oncology and animal health offsetting Gardasil headwinds. The company’s diversified pipeline and strategic reinvestment position it well for long-term growth. While near-term risks persist, Merck’s focus on innovation and operational efficiency underscores its commitment to delivering shareholder value and advancing patient care.